KRAS and lung adenocarcinoma: In KRAS-mutant lung adenocarcinomas, significant activation of NRF1 targets was associated with worse prognosis (Figure S24E), consistent with NRF1’s role as a regulator of the proteasome pathway,48 a key dependency in KRAS-mutant cancers.49